A new noninvasive technique for estimating hepatic triglyceride: will liver biopsy become redundant in diagnosing non-alcoholic fatty liver disease? by unknown
Obesity: exploring the causes, consequences and solutions
Betzel and Drenth BMC Medicine 2014, 12:152
http://www.biomedcentral.com/1741-7015/12/152COMMENTARY Open AccessA new noninvasive technique for estimating
hepatic triglyceride: will liver biopsy become
redundant in diagnosing non-alcoholic fatty
liver disease?
Bark Betzel1 and Joost PH Drenth2*Abstract
Obesity and metabolic syndrome are healthcare problems that continue to rise in frequency worldwide. Both
phenotypes are a strong predictor for development of liver steatosis in the context of non-alcoholic fatty liver
disease or non-alcoholic steatohepatitis. Ultrasound may detect steatosis, but its sensitivity is limited and liver
biopsy is still considered to be the gold standard. Less invasive techniques that accurately quantify liver steatosis
are warranted. Jiménez-Agüero and colleagues propose that multi-echo magnetic resonance imaging might be
such a diagnostic tool. They validated multi-echo magnetic resonance imaging with measured hepatic triglyceride
concentration. Their results show that this innovative technique measures the grade of steatosis in different clinical
situations. Therefore, multi-echo magnetic resonance imaging might be considered for monitoring liver steatosis as
an intermediate endpoint. Wide clinical applicability is limited though, as it does not allow differentiation between
non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
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The incidence of obesity is increasing worldwide at an
alarmingly fast pace, mainly because of a combination of
cultural, social, and economic factors that affect lifestyle.
Currently, one out of every three Americans is considered
to be obese. Obesity is the main driver for the onset of
metabolic syndrome, which is a group of metabolic
abnormalities that share the cardiovascular risk factors
hypertension, dyslipidemia, and hyperglycemia. Presence
of metabolic syndrome including obesity is a strong pre-
dictor for hepatic steatosis, defined as lipid deposition in
hepatocytes. Its phenotype ranges from non-alcohol fatty
liver disease (NAFLD), to non-alcoholic steatohepatitis
(NASH - fatty changes with inflammation and hepatocel-
lular injury or fibrosis), to advanced fibrosis and cirrhosis.* Correspondence: joostphdrenth@cs.com
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article, unless otherwise stated.Similar to obesity, NAFLD has reached epidemic
proportions with a prevalence of 20% to 30% in western
populations [1]. Because NAFLD constitutes a risk factor
for NASH, it is to be expected that the prevalence of com-
plicated liver disease in patients with obesity and meta-
bolic syndrome will rise. As such, prevention of metabolic
syndrome is a therapeutic target and lifestyle changes for
patients at risk should be encouraged.
The question then arises, how to detect liver steatosis
[2]? Ultrasound is by far the most frequently used modality
to detect liver steatosis. Fatty filtration of the liver produces
a diffuse increase in echogenicity (a bright liver) and
blurring of vascular margins and the diaphragm. Ultra-
sound, however, has some inherent disadvantages, such
as a limited sensitivity to detect steatosis when less
than 30% of hepatocytes contains fat, and its accuracy
is compromised in patients who are obese. In addition,
ultrasound cannot identify relevant liver disease in the
context of NASH, such as steatohepatitis or fibrosis.entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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entiate it from NASH is liver biopsy. A liver biopsy should
be considered in patients with liver steatosis on imaging
who are at increased risk of steatohepatitis and advanced
fibrosis, such as patients with competing etiologies for
hepatic steatosis (for example, diabetes mellitus) and with
co-existing liver disease. However, the invasive nature of
liver biopsy with its risk for major complications, such as
bleeding in approximately 1% of cases [3], precludes wide-
spread use. Therefore, an accurate, easy to conduct, and
less invasive technique is needed in diagnosing NAFLD
[4]. Both computed tomography and magnetic resonance
imaging (MRI) are more sensitive modalities for quantifying
steatosis. However, none of these imaging techniques have
sufficient sensitivity and specificity to stage the disease
and cannot distinguish between NAFLD and NASH [5].
Jiménez-Agüero and colleagues [6] performed a rigor-
ously designed and well-executed prospective study in 129
patients where hepatic lipid concentration was determined
by three different methods. They performed histopatho-
logical examination of liver biopsies, measured hepatic
triglyceride concentration from liver biopsy specimen
(Folch method), and established liver fat fraction using
multi-echo MRI. Multi-echo MRI was performed within
24 hours before collection of the biopsy, so no changes in
hepatic fat content could occur due to the time interval.
To improve diagnostic accuracy, they developed an equa-
tion that took into account the multi-echo MRI data, which
was then validated in an additional cohort of 31 patients.
After validation of the multi-echo MRI, this tool was tested
to see if it could detect changes in liver fat content over
time in obese patients. From the original cohort of 97 obeseNormal 
Figure 1 Bariatric surgery leads to a decrease of liver steatosis, whichpatients, 86 underwent bariatric surgery while 11 were
treated by partial liver resection. In total, 66 (56 and 11)
patients received a second multi-echo MRI one year
after surgery.
Applicability
Jiménez-Agüero and colleagues [6] validated a noninvasive
tool (multi-echo MRI) with a biochemical quantification
of hepatic triglyceride concentration. The key finding of
the study is that accurate grading of steatosis with help
of multi-echo MRI becomes possible. There are clear
advantages of a noninvasive technique, especially when it
comes to follow-up of patients with NAFLD undergoing
treatment. In their hands, multi-echo MRI was able to
predict the concentration of liver fat and demonstrated
the improvement of steatosis after bariatric surgery. By
contrast, in obese patients who underwent partial liver re-
section, hepatic steatosis remained unchanged. As such,
multi-echo MRI allows monitoring of changes in hepatic
fat content in different clinical situations.
Unfortunately, the applicability of this study in clinical
practice stops there; it allows the differentiation between
grades of steatosis. The technique does not differentiate
between steatosis, steatohepatitis, and fibrosis. The ability
to perform the latter is essential because the presence of
steatohepatitis and fibrosis affects prognosis and influ-
ences disease management [7].
Bariatric surgery
The researchers took bariatric surgery as a model. Although
patients eligible for bariatric surgery have a substantial risk
for metabolic syndrome, it should be noticed that not allMRI
Steatosis
Bariatric surgery
can be detected by multi-echo magnetic resonance imaging.
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tients did not have steatosis. The data of Jiménez-Agüero
et al. [6] suggests that bariatric surgery reduces the liver
fat fraction as measured by multi-echo MRI (Figure 1). Al-
though bariatric surgery has superior effects on obesity
and diabetes mellitus compared to conservative treatment
[8], findings regarding beneficial effects on NAFLD and
NASH are inconclusive [9]. Indeed, no randomized con-
trolled trials have examined the effect of bariatric surgery
on other components of metabolic syndrome, such as
NAFLD or NASH. However, some anecdotal reports (such
as the paper of Jiménez-Agüero et al. [6]) suggest re-
gression and/or histological improvement of NAFLD
or NASH after weight loss induced by bariatric surgery
[10]. A rigorous clinical trial suggested that weight loss
achieved through intensive lifestyle changes leads to
improvement of histological signs of NASH [11].
Future perspectives
Multi-echo MRI is an attractive noninvasive technique to
measure the grade of steatosis. However, as long as the
grade of hepatic fat has no direct effect on liver disease, in
contrast to NASH, multi-echo MRI at best measures an
intermediate endpoint. Histopathological assessment of
hepatitis and fibrosis, by means of a biopsy, remains the
gold standard to differentiate between NAFLD and NASH.
Therefore the use of multi-echo MRI is probably restricted
to clinical research. On a different note, we encourage the
development of new noninvasive techniques to grade stea-
tosis because they can be of great value in patients with
NASH. There, these techniques can play a role in moni-
toring the reduction of steatosis through lifestyle changes.
In such cases, steatosis is a worthwhile intermediate end-
point that is associated with improved histological lesions
that occur in NASH, such as hepatitis, hepatocellular bal-
looning and fibrosis.
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